Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFAMETHOPRIM DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFAMETHOPRIM DS.
SODIUM SULFACETAMIDE vs SULFAMETHOPRIM-DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Sulfamethoprim-DS is a combination of sulfamethoxazole, a dihydropteroate synthase inhibitor, and trimethoprim, a dihydrofolate reductase inhibitor. The sequential inhibition of folate synthesis leads to bactericidal activity.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
Sulfamethoprim-DS (trimethoprim 160 mg-sulfamethoxazole 800 mg) orally every 12 hours for 10-14 days for uncomplicated UTI; for Pneumocystis jirovecii pneumonia: 3-5 mg/kg/day (based on TMP) orally or IV divided every 6-8 hours for 21 days.
None Documented
None Documented
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
Terminal elimination half-life of sulfamethoxazole is 9-11 hours (prolonged to 20-50 hours in severe renal impairment). Clinically, this supports twice-daily dosing in normal renal function; dose adjustment required for CrCl <30 mL/min.
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal excretion of unchanged drug (50-70%) and metabolites (primarily N4-acetylated form, 15-30%); biliary/fecal excretion accounts for <5%.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic